Cargando…
Psoas and Mediastinal Abscesses during Intravenous Tocilizumab Treatment in Multicentric Castleman Disease
Tocilizumab has been used to treat idiopathic multicentric Castleman disease (iMCD). As tocilizumab prevents interleukin-6 from exerting pro-inflammatory effects, there is some concern about a delayed diagnosis of severe infections during tocilizumab treatment. Although serious infections during toc...
Autores principales: | Togitani, Kazuto, Ogasawara, Fumiya, Arakawa, Yu, Sugimura, Natsuki, Miyazaki, Ryohei, Kojima, Kensuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970794/ https://www.ncbi.nlm.nih.gov/pubmed/35732449 http://dx.doi.org/10.2169/internalmedicine.9519-22 |
Ejemplares similares
-
Glucocorticoid-induced redistribution lymphocytosis in mantle cell lymphoma with hyaline vascular Castleman disease-like features
por: Togitani, Kazuto, et al.
Publicado: (2021) -
Sustained remission of Multicentric Castleman Disease in children treated with tocilizumab
por: Galeotti, C, et al.
Publicado: (2011) -
Psoas abscess during treatment with intravenous tocilizumab in a patient with rheumatoid arthritis: a case-based review
por: Vajdić, Ines Doko, et al.
Publicado: (2021) -
Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease
por: Arakawa, Akira, et al.
Publicado: (2021) -
Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab
por: Aita, Tetsuro, et al.
Publicado: (2020)